Cigna eases burden of high cost gene therapies; plan doesn’t account for lack of benefit

As the Medicaid best price rule continues to stymie attempts to move beyond one-time payments for gene therapies, some payers and pharmacy benefit managers are working to soften the blow for their clients and patients. A new model announced by Cigna would allow employers to opt into a new benefit design that would spread the costs to the employer out over time, but does not address what happens when and if the